Renovaro Biosciences Stock (NASDAQ:ENOB)


OwnershipFinancialsChart

Previous Close

$0.70

52W Range

$0.39 - $2.99

50D Avg

$0.65

200D Avg

$1.14

Market Cap

$45.38M

Avg Vol (3M)

$254.60K

Beta

0.94

Div Yield

-

ENOB Company Profile


Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Feb 07, 2018

Website

ENOB Performance


ENOB Financial Summary


Mar 23Jun 22Jun 21
Revenue---
Operating Income-$-116.08M$-23.40M
Net Income-$-113.43M$-26.72M
EBITDA-$-22.58M$-23.00M
Basic EPS-$-2.16$-0.57
Diluted EPS-$-2.16$-0.57

Fiscal year ends in Mar 23 | Currency in USD

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
CSBRChampions Oncology, Inc.
ANTXAN2 Therapeutics, Inc.
MNOVMediciNova, Inc.
PHVSPharvaris N.V.
RZLTRezolute, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
ELYMEliem Therapeutics, Inc.